Lilly Not Ducking M&A, But Will Play To Strengths In Cancer And Diabetes

The Indiana-based big pharma will focus on product-level acquisitions in its core areas of strengths now that it has rounded out its animal health business with its $5.4 billion acquisition of Novartis Animal Health.